If you’ve been diagnosed with an eye condition later in life, you’ve probably noticed that most “eye health” conversations focus on vitamins.1 Those can be important, but researchers are also exploring a different strategy: helping retinal cells survive stress.2
That’s where TUDCA comes in.
What is TUDCA?
TUDCA is tauroursodeoxycholic acid, a hydrophilic bile acid that has been studied for neuroprotective effects across multiple disease models, including neurodegenerative conditions.3 In plain English: it’s a compound researchers are interested in because it may help cells tolerate stress and avoid premature cell death.4
Why Researchers Are Interested In TUDCA For The Retina
Many vision-threatening conditions cause progressive stress and damage within the retina.5 The retina contains photoreceptors (light-sensing cells) and other specialized neural cells that are sensitive to oxidative stress, inflammation, and cellular “misfolding” stress.6
Across multiple preclinical studies, TUDCA has shown protective effects in models of retinal degeneration, including retinitis pigmentosa, diabetic retinopathy, and retinal detachment.7
Three Ways TUDCA May Help Protect Vision (Based On Preclinical Research)
Helps Reduce Cellular Stress
Two types of stress show up repeatedly in retinal disease research:
- Oxidative Stress (Excess Reactive Oxygen Species), and
- Endoplasmic reticulum (ER) stress (stress related to protein folding and cellular “quality control”)
TUDCA is often described as a “chemical chaperone,” meaning it may help cells manage ER stress more effectively.8 ER-stress reduction is also a key mechanism discussed in cardiac remodeling models, reinforcing the broader “chemical chaperone” rationale.9
Helps Prevent Apoptosis (Programmed Cell Death)
In many degenerative eye conditions, the issue isn’t just irritation or inflammation—it’s the loss of retinal cells over time.10 In animal and cell models, TUDCA has been shown to reduce markers of apoptosis in retinal cells, including photoreceptors and retinal pigment epithelial (RPE) cells.11
Supports Mitochondrial Stability
Mitochondria are the cell’s energy centers. When mitochondria become unstable, cells are more likely to malfunction or die.12 Research suggests TUDCA may help stabilize mitochondrial membranes, which is one reason it’s studied for broader neuroprotection.13
Where The Evidence Looks Most Promising
Retinitis Pigmentosa
In genetic models of Retinitis Pigmentosa, TUDCA has been associated with slower retinal thinning and better preservation of retinal structure.14 Photoreceptor structure/function preservation has also been shown in rd10 models through early postnatal stages.15 That doesn’t mean it’s a proven human treatment—but it does help explain why researchers keep investigating it.16
Diabetic Retinopathy
Diabetic Retinopathy is one of the leading causes of blindness, and projections suggest the number of adults affected will continue to rise in the coming decades.17 Typical treatments often focus on later-stage vascular changes (like abnormal blood vessel growth).18 But research has also shown that neuronal damage can occur early—before obvious vascular damage is detected on an exam.19
That’s why the idea of early neuroprotection is so compelling: it aims to support retinal function before damage becomes harder to reverse.20 And newer work has explored detection and potential restorative approaches in preclinical DR.21
A Smart “Vision Support Stack”
If you’re thinking in terms of whole-body wellness and eye resilience, many people build a plan that includes:22
- Macular pigments: lutein + zeaxanthin
- Antioxidant support: vitamin C, glutathione, alpha lipoic acid, NAC23
- Mitochondrial support: CoQ10, magnesium, B vitamins24
- Circulation support: bilberry, ginkgo
- Inflammation balance: omega-3s, turmeric25
- Retinal Detachment
Some research suggests that bile acids can cross into ocular tissues and may have protective potential in retinal detachment.26 This remains an emerging area, but it adds to the overall rationale for continued study.27
Reality Check: What We Still Don’t Know
Much of the strongest evidence for TUDCA and vision protection comes from animal and laboratory models.28 Researchers are calling for large, well-designed human clinical trials to confirm:29
- Who benefits most
- The best dose and duration
- Long-term safety for eye-specific outcomes
If you have an eye disease diagnosis, take medications, or have liver/gallbladder concerns, be sure to discuss your supplements with your clinician before starting a new supplement.30
Summary
TUDCA is one of the more interesting “next wave” compounds being studied for retinal protection because it targets cellular stress and survival pathways.31 The preclinical evidence is encouraging across multiple retinal disease models, but human clinical trials are still needed to confirm real-world outcomes.32
- Jackson G.R., Barber A.J. Visual dysfunction associated with diabetic retinopathy. Curr. Diabetes Rep. 2010;10:380–384. doi: 10.1007/s11892-010-0132-4 ↩
- Daruich A., Picard E., Boatright J.H., Behar-Cohen F. Review: The bile acids urso- and tauroursodeoxycholic acid as neuroprotective therapies in retinal disease. Mol. Vis. 2019;25:610–624. ↩
- Zangerolamo L., Vettorazzi J.F., Rosa L.R.O., Carneiro E.M., Barbosa H.C.L. The bile acid TUDCA and neurodegenerative disorders: An overview. Life Sci. 2021;272:119252. doi: 10.1016/j.lfs.2021.119252. ↩
- Elia A.E., Lalli S., Monsurrò M.R., Sagnelli A., Taiello A.C., Reggiori B., La Bella V., Tedeschi G., Albanese A. Tauroursodeoxycholic acid in the treatment of patients with amyotrophic lateral sclerosis. Eur. J. Neurol. 2016;23:45–52. doi: 10.1111/ene.12664. ↩
- Antonetti D., Barber A., Bronson S., Freeman W., Gardner T., Jefferson L.S., Kester M., Kimball S.R., Krady J.K., LaNoue K.F., et al. Diabetic retinopathy: Seeing beyond glucose-induced microvascular disease. Diabetes. 2006;55:2401–2411. doi: 10.2337/db05-1635. ↩
- Fletcher E.L., Phipps J.A., Ward M.M., Puthussery T., Wilkinson-Berka J.L. Neuronal and glial cell abnormality as predictors of progression of diabetic retinopathy. Curr. Pharm. Des. 2007;13:2699–2712. doi: 10.2174/138161207781662920 ↩
- Daruich A., Picard E., Boatright J.H., Behar-Cohen F. Review: The bile acids urso- and tauroursodeoxycholic acid as neuroprotective therapies in retinal disease. Mol. Vis. 2019;25:610–624. ↩
- Ceylan-Isik A.F., Sreejayan N., Ren J. Endoplasmic reticulum chaperon tauroursodeoxycholic acid alleviates obesity-induced myocardial contractile dysfunction. J. Mol. Cell Cardiol. 2011;50:107–116. doi: 10.1016/j.yjmcc.2010.10.023. ↩
- Rani S., Sreenivasaiah P.K., Kim J.O., Lee M.Y., Kang W.S., Kim Y.S., Ahn Y., Park W.J., Cho C., Kim D.H. Tauroursodeoxycholic acid (TUDCA) attenuates pressure overload-induced cardiac remodeling by reducing endoplasmic reticulum stress. PLoS ONE. 2017;12:e0176071. doi: 10.1371/journal.pone.0176071. ↩
- Noailles A., Fernandez-Sanchez L., Lax P., Cuenca N. Microglia activation in a model of retinal degeneration and TUDCA neuroprotective effects. J. Neuroinflammation. 2014;11:186. doi: 10.1186/s12974-014-0186-3. ↩
- Gaspar J.M., Martins A., Cruz R., Rodrigues C.M.P., Ambrósio A.F., Santiago A.R. Tauroursodeoxycholic acid protects retinal neural cells from cell death induced by prolonged exposure to elevated glucose. Neuroscience. 2013;253:380–388. doi: 10.1016/j.neuroscience.2013.08.053. ↩
- Wu X., Liu C., Chen L., Du Y.F., Hu M., Reed M.N., Long Y., Suppiramaniam V., Hong H., Tang S.-S. Protective effects of tauroursodeoxycholic acid on lipopolysaccharide-induced cognitive impairment and neurotoxicity in mice. Int. Immunopharmacol. 2019;72:166–175. doi: 10.1016/j.intimp.2019.03.065. ↩
- Moreira S., Fonseca I., Nunes M.J., Rosa A., Lemos L., Rodrigues E., Carvalho A.N., Outeiro T.F., Rodrigues C., Gama M.J., et al. Nrf2 activation by tauroursodeoxycholic acid in experimental models of Parkinson’s disease. Exp. Neurol. 2017;295:77–87. doi: 10.1016/j.expneurol.2017.05.009. ↩
- Drack A.V., Dumitrescu A.V., Bhattarai S., Gratie D., Stone E.M., Mullins R., Sheffield V.C. TUDCA slows retinal degeneration in two different mouse models of retinitis pigmentosa and prevents obesity in Bardet-Biedl syndrome type 1 mice. Investig. Ophthalmol. Vis. Sci. 2012;53:100–106. doi: 10.1167/iovs.11-8544 ↩
- Phillips M.J., Walker T.A., Choi H.-Y., Faulkner A.E., Kim M.K., Sidney S.S., Boyd A.P., Nickerson J.M., Boatright J.H., Pardue M.T. Tauroursodeoxycholic acid preserves photoreceptor structure and function in the rd10 mouse through post-natal day 30. Investig. Ophthalmol. Vis. Sci. 2008;49:2148–2155. doi: 10.1167/iovs.07-1012. ↩
- Lawson E.C., Bhatia S.K., Han M.K., Aung M.H., Ciavatta V., Boatright J.H., Pardue M.T. Tauroursodeoxycholic Acid Protects Retinal Function and Structure in rd1 Mice. Adv. Exp. Med. Biol. 2016;854:431–436. doi: 10.1007/978-3-319-17121-0_57 ↩
- National Eye Institute Projections for Diabetic Retinopathy (2010–2030–2050) (accessed on 9 April 2018);2010 ↩
- Antonetti D., Barber A., Bronson S., Freeman W., Gardner T., Jefferson L.S., Kester M., Kimball S.R., Krady J.K., LaNoue K.F., et al. Diabetic retinopathy: Seeing beyond glucose-induced microvascular disease. Diabetes. 2006;55:2401–2411. doi: 10.2337/db05-1635. ↩
- Pardue M.T., Barnes C.S., Kim M.K., Aung M.H., Amarnath R., Olson D.E., Thulé P.M. Rodent Hyperglycemia-Induced Inner Retinal Deficits are Mirrored in Human Diabetes. Transl. Vis. Sci. Technol. 2014;3:6. doi: 10.1167/tvst.3.3.6. ↩
- Aung M.H., Kim M.K., Olson D.E., Thule P.M., Pardue M.T. Early visual deficits in streptozotocin-induced diabetic long evans rats. Investig. Ophthalmol. Vis. Sci. 2013;54:1370–1377. doi: 10.1167/iovs.12-10927 ↩
- Motz C.T., Chesler K.C., Allen R.S., Bales K.L., Mees L.M., Feola A.J., Maa A.Y., Olson D.E., Thule P.M., Iuvone P.M., et al. Novel Detection and Restorative Levodopa Treatment for Preclinical Diabetic Retinopathy. Diabetes. 2020;69:1518–1527. doi: 10.2337/db19-0869 ↩
- Pardue M.T., Allen R.S. Neuroprotective strategies for retinal disease. Prog. Retin. Eye Res. 2018;65:50–76. doi: 10.1016/j.preteyeres.2018.02.002. ↩
- ibid ↩
- Zangerolamo L., Vettorazzi J.F., Rosa L.R.O., Carneiro E.M., Barbosa H.C.L. The bile acid TUDCA and neurodegenerative disorders: An overview. Life Sci. 2021;272:119252. doi: 10.1016/j.lfs.2021.119252. ↩
- Zangerolamo L., Vettorazzi J.F., Rosa L.R.O., Carneiro E.M., Barbosa H.C.L. The bile acid TUDCA and neurodegenerative disorders: An overview. Life Sci. 2021;272:119252. doi: 10.1016/j.lfs.2021.119252. ↩
- Daruich A., Jaworski T., Henry H., Zola M., Youale J., Parenti L., Naud M.-C., Delaunay K., Bertrand M., Berdugo M., et al. Oral Ursodeoxycholic Acid Crosses the Blood Retinal Barrier in Patients with Retinal Detachment and Protects Against Retinal Degeneration in an Ex Vivo Model. Neurotherapeutics. 2021 doi: 10.1007/s13311-021-01009-6 ↩
- Daruich A., Picard E., Boatright J.H., Behar-Cohen F. Review: The bile acids urso- and tauroursodeoxycholic acid as neuroprotective therapies in retinal disease. Mol. Vis. 2019;25:610–624. ↩
- Fernandez-Sanchez L., Bravo-Osuna I., Lax P., Arranz-Romera A., Maneu V., Esteban-Perez S., Pinilla I., Puebla-González M.D.M., Herrero-Vanrell R., Cuenca N. Controlled delivery of tauroursodeoxycholic acid from biodegradable microspheres slows retinal degeneration and vision loss in P23H rats. PLoS ONE. 2017;12:e0177998. doi: 10.1371/journal.pone.0177998. ↩
- Daruich A., Picard E., Boatright J.H., Behar-Cohen F. Review: The bile acids urso- and tauroursodeoxycholic acid as neuroprotective therapies in retinal disease. Mol. Vis. 2019;25:610–624. ↩
- Zangerolamo L., Vettorazzi J.F., Rosa L.R.O., Carneiro E.M., Barbosa H.C.L. The bile acid TUDCA and neurodegenerative disorders: An overview. Life Sci. 2021;272:119252. doi: 10.1016/j.lfs.2021.119252. ↩
- Tao Y., Dong X., Lu X., Qu Y., Wang C., Peng G., Zhang J. Subcutaneous delivery of tauroursodeoxycholic acid rescues the cone photoreceptors in degenerative retina: A promising therapeutic molecule for retinopathy. Biomed. Pharmacother. 2019;117:109021. doi: 10.1016/j.biopha.2019.109021 ↩
- Daruich A., Picard E., Boatright J.H., Behar-Cohen F. Review: The bile acids urso- and tauroursodeoxycholic acid as neuroprotective therapies in retinal disease. Mol. Vis. 2019;25:610–624. ↩
